This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Bernard A. Schwetz, DVM,PhD

JAMA. 2001;285:2186.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved two new drugs, bimatoprost ophthalmic solution, 0.03% (Lumigan, Allergan Inc, Irvine, Calif), and travoprost ophthalmic solution, 0.004% (Travatan, Alcon Universal Ltd, Fort Worth, Tex), for reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Both products provide additional alternatives for patients who are intolerant of other IOP-lowering medications or insufficiently responsive (failure to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.

Bimatoprost and travoprost were studied in separate multicenter, randomized, double-blind, active-controlled, parallel-group clinical trials in patients with open-angle glaucoma or ocular hypertension with a mean baseline IOP of 25 mm Hg to 27 mm Hg. The IOP-lowering effect of bimatoprost used once daily (in the evening) in 750 patients for one year was 7 to 8 mm Hg. Travoprost used once daily (in the evening) in 401 patients for a 6-month . . . [Full Text of this Article]

Acting Principal Deputy Commissioner
Food and Drug Administration

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?